GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Additional Paid-In Capital

SynAct Pharma AB (OSTO:SYNACT) Additional Paid-In Capital : kr649.19 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Additional Paid-In Capital?


SynAct Pharma AB's quarterly additional paid-in capital increased from Sep. 2023 (kr589.38 Mil) to Dec. 2023 (kr646.57 Mil) and increased from Dec. 2023 (kr646.57 Mil) to Mar. 2024 (kr649.19 Mil).

SynAct Pharma AB's annual additional paid-in capital increased from Dec. 2021 (kr193.60 Mil) to Dec. 2022 (kr394.84 Mil) and increased from Dec. 2022 (kr394.84 Mil) to Dec. 2023 (kr646.57 Mil).

SynAct Pharma AB Additional Paid-In Capital Historical Data

The historical data trend for SynAct Pharma AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Additional Paid-In Capital Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 89.55 119.40 193.60 394.84 646.57

SynAct Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 585.05 586.43 589.38 646.57 649.19

SynAct Pharma AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

SynAct Pharma AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Additional Paid-In Capital
Comparable Companies
XSAT:CURAS OSTO:XBRANE OSTO:CANTA OSTO:ITECH OSTO:DMYD B OSTO:INIT OSTO:ONCO OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8F8:Germany
Address
Sheelevagen 2, Lund, SWE, 223 81
Website
https://www.synactpharma.se
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines